Cosentyx (secukinumab) is used for the continuous management of several conditions involving inflammatory or irritative processes which can lead to joint, spinal, or skin changes. It is indicated for treating a range of conditions including plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The therapeutic goal is generally to control inflammation, which can help manage related symptoms and assist with functional stability.

---

This medication is relevant for easing challenging symptoms associated with chronic, active diseases like moderate to severe plaque psoriasis, Hidradenitis Suppurativa, Ankylosing Spondylitis (AS), and Juvenile Psoriatic Arthritis. It contributes to easing the overall symptom load by addressing both skin manifestations (redness, scaling, nodules) and musculoskeletal inflammation (joint pain, stiffness).

“The primary purpose of this therapy is to provide supportive relief and help maintain a sense of stability when symptoms are more noticeable.”

---

Quick Fact: Support for Symptoms of Chronic Inflammation

Quick Fact: Support for Symptoms of Chronic Inflammation The medication is commonly used when supportive symptom management is appropriate for conditions where symptoms may intensify temporarily, providing relief across both skin and joint therapeutic domains. It assists with maintaining functional stability and helps improve day-to-day comfort.

Regulatory References

1. Cosentyx is indicated for treating a range of conditions

Eligibility Map: Who Can and Cannot Use Cosentyx — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults (18+): Eligible for all approved indications. Pediatric Patients: Eligibility is specific to age: 6 years for Plaque Psoriasis, 2 years for Psoriatic Arthritis (US label), and 4 years for Enthesitis-Related Arthritis (US label).
Populations for whom use is contraindicated	Patients with a history of serious hypersensitivity reaction to secukinumab or any excipients. Initiation is not recommended in patients with a clinically important, active infection, including active Tuberculosis (TB).
Pregnancy and lactation eligibility status	Pregnancy: Use should preferably be avoided as a precautionary measure due to limited human data. Lactation: A decision must be made to discontinue breastfeeding or discontinue therapy due to unknown excretion into human milk.
Eligibility-related restrictions	Caution should be exercised when prescribing to patients with a history of or current Inflammatory Bowel Disease (IBD), as well as those with a history of chronic or recurrent infection. Use in patients with renal or hepatic impairment has not been specifically studied, and no dose recommendations can be made for these populations.

Interactions with other medicines and products

Cosentyx (secukinumab) has officially documented interaction patterns primarily concerning its immunosuppressive activity and its effect on metabolic enzymes.

Contraindicated Combinations and Timing Rules

The co-administration of secukinumab with live vaccines is a formal contraindicated combination . The medicine's action as an immunosuppressant biologic may reduce the immune response to the vaccine, increasing the risk of adverse outcomes. Consequently, a mandatory regulatory restriction requires that all age-appropriate immunizations must be completed prior to the initiation of secukinumab treatment. Non-live (inactivated) vaccines can generally be co-administered, as regulatory data suggests the medicine does not suppress the necessary antibody response.

Pharmacokinetic Interactions

Secukinumab can cause a pharmacokinetic interaction through the normalization of the CYP450 enzyme system. During chronic inflammatory conditions, elevated cytokines can suppress the activity of these drug-metabolizing enzymes. When secukinumab reduces this inflammation, the resulting enzyme normalization may alter the plasma exposure of co-administered medicines, especially those classified as narrow therapeutic index substrates for CYP450 enzymes. This potential change in systemic exposure is the basis for regulatory caution. Official documents do not specify interactions with food, alcohol, herbal products, or drug transporters.

Secukinumab is a fully human monoclonal antibody that operates via selective neutralizing antagonism within a specific inflammatory pathway.

Selective Neutralization of Interleukin-17A ( IL-17A)

Secukinumab binds directly and with high affinity to the free pro-inflammatory cytokine IL-17A, effectively sequestering the molecule and preventing it from engaging its specific receptor ( IL-17R) on cell surfaces. This action involves selective blockade of the IL-17A pathway and does not target the TNF-alpha or IL-23 inflammatory axes.

Interruption of Downstream Inflammatory Cascades

By blocking the IL-17A signal, the drug suppresses the subsequent activation of key intracellular signaling cascades, such as NF-kappa B and MAPK, within target cells. This interference reduces the gene transcription and release of numerous pro-inflammatory chemokines and cytokines, which modulate the attraction of immune cells.

Modulation of Tissue Activity and Structural Mediators

This mechanistic sequence translates into physiological effects at the tissue level, limiting the excessive recruitment of inflammatory cells, such as neutrophils. It also modulates mediators involved in cell turnover and influences those involved in progressive structural changes.

Cosentyx (secukinumab) is administered through one of two official routes: a subcutaneous (SC) injection using a pre-filled pen or syringe, or an intravenous (IV) infusion administered by a healthcare professional. The official treatment protocol is structured around two distinct phases: an initial intensive period and a long-term maintenance schedule.

The initial loading phase requires five separate doses given weekly at Weeks 0, 1, 2, 3, and 4 for all approved conditions. Following this, the maintenance phase typically transitions to a dose administered once every four weeks ( q4wk). The standard maintenance dose is 300 mg for adult plaque psoriasis and Hidradenitis Suppurativa, while 150 mg is standard for Psoriatic Arthritis and Ankylosing Spondylitis. For cases of inadequate response, the maintenance frequency may be intensified to 300 mg administered every two weeks ( q2wk).

Specialized instructions apply to administration technique. SC devices must be allowed to warm to room temperature before injection and must not be shaken. The IV route requires the drug to be diluted and administered as a 30-minute infusion under appropriate supervision. For pediatric patients, the administration is based on the patient's weight, requiring a dose of either 75 mg or 150 mg. If a maintenance dose is missed, official guidance directs administering the dose as soon as possible, and then resuming the regular scheduled pattern.

Research evidence / Overview of studies for Cosentyx

---

Evidence for Use in Plaque Psoriasis

Research examined secukinumab for the management of Plaque Psoriasis, a condition where symptoms may vary in intensity and are linked to underlying inflammatory states. Studies conducted were mainly large, short-term randomized controlled trials (RCTs) in adults and children. Researchers monitored outcomes related to physical discomfort, including the degree of skin clearance (PASI and IGA scores).

Studies reported patterns where a higher proportion of patients in the treatment groups were associated with predefined levels of skin clearance compared to the placebo group. Research also explored short-term symptom changes, reporting that in some studies, different measurements were observed between the various dose groups at the 12-week assessment.

Evidence for Use in Psoriatic Arthritis and Axial Spondyloarthritis

Secukinumab was evaluated in studies for Psoriatic Arthritis and Ankylosing Spondylitis (AS), conditions associated with functional limitations and joint inflammation. Pivotal placebo-controlled RCTs focused on changes in joint symptoms (ACR criteria) and spinal symptoms (ASAS 20/40). Studies also examined the progressive structural damage to the joints using X-ray assessments.

Findings describe patterns where a portion of the studied patients met the ACR or ASAS response criteria over defined periods. Long-term follow-up from open-label extension studies describes that measurements of joint and spinal symptom patterns were observed in a subset of patients who continued treatment for up to five years.

Gaps in Evidence and Areas of Uncertainty

While extensive research has been conducted, certain areas of evidence remain limited. The majority of information regarding long-term effects are not fully established with the same certainty as the initial, short-term findings because the data are based on open-label extension studies that were not designed as blinded or placebo-controlled studies.

Additionally, data for certain subgroups—such as patients with specific coexisting medical conditions or very narrow age ranges—is often limited. Comparative evidence against some newer biologic therapies is also not yet available in prospective, head-to-head trials. Therefore, while research describes patterns, it highlights what is known—and what is still uncertain—and does not determine whether an individual will respond similarly.

Common questions about Cosentyx (FAQ)

Q: How quickly do people typically start to notice any difference after starting Cosentyx?

A: Clinical studies for some conditions, such as Psoriatic Arthritis, have described patients observing initial signs of improvement within a few weeks. However, the timeline for achieving more significant symptom reduction is often longer, with major measurements typically taken by 12 or 16 weeks in research.

Q: What happens if I miss a scheduled dose of Cosentyx?

A: According to the official product information, official guidance describes administering the missed maintenance dose as soon as possible, with the instruction to then resume the regular scheduled pattern.

Q: Does Cosentyx change how my other prescription medicines work?

A: Regulatory documents indicate that secukinumab has the potential to alter the way the body processes some other medicines. This potential change is related to the drug’s observed influence on certain enzymes that process other medications, which is why regulatory caution is noted for medications with a narrow therapeutic index.

Q: What are the rules about getting vaccines while using Cosentyx?

A: Official guidance states that the use of live vaccines is formally contraindicated, meaning it is not to be administered while using this medication. Non-live (inactivated) vaccines can generally be co-administered. Official recommendations state that all age-appropriate immunizations should be completed prior to the initiation of Cosentyx treatment.

Q: Can people with liver or kidney problems use Cosentyx?

A: Official documents state that the use of this drug in patients with renal or hepatic impairment (kidney or liver problems) has not been specifically studied. Due to this absence of specific research, official documents contain no specific guidance or dose recommendations for these patient populations.

Q: Does Cosentyx affect the immune system's ability to fight common colds?

A: The official product information lists upper respiratory tract infections and cold symptoms (nasopharyngitis) among the most commonly reported side effects in clinical trials. These are the types of minor infections that have been reported in the drug’s adverse reactions profile.

Q: Are there any foods or supplements that should be avoided while using Cosentyx?

A: Official regulatory documents state that no specific interactions with food, alcohol, or herbal products are known. The regulatory documents do not specify any restrictions or warnings regarding interactions with food, alcohol, or herbal products.

Q: Can Cosentyx be used for conditions other than psoriasis or arthritis?

A: Regulatory agencies, such as the FDA, have granted official approval for Cosentyx to treat a specific set of conditions. These conditions include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa.

Q: What are the most common things people feel when they first start Cosentyx?

A: The most commonly reported adverse reactions in clinical trials (occurring in over 1% of patients) are cold symptoms (nasopharyngitis), diarrhea, and upper respiratory tract infections. These are the most frequent effects observed by researchers.

Q: Does research show that Cosentyx is a long-term treatment?

A: Research studies, including open-label extension studies, have observed patterns of joint and spinal symptom measurements in a subset of patients who continued treatment for up to five years. This demonstrates the existence of long-term data for the management of chronic conditions.

Q: Can Cosentyx affect fertility in men or women?

A: Official documents state that there are insufficient data on the use of this drug to inform a related risk to human fertility. The official documentation includes information stating that women of childbearing potential should use an effective method of contraception during treatment and for a period of at least 20 weeks after the final dose.

Q: Do the official studies cover what happens if you take Cosentyx for 5 years or more?

A: Long-term follow-up from open-label extension studies describes that measurements were observed in a subset of patients who continued treatment for up to five years. It is noted that the certainty of these data is limited because they are not based on initial, blinded, or placebo-controlled studies.

Q: Can Cosentyx be shipped to my house, and does it need refrigeration?

A: According to the handling instructions, Cosentyx must be stored in a refrigerator within the temperature range of 36 F to 46 F. The medication may be stored at room temperature (not exceeding 86 F) for a single period of up to four days.

Q: Are there any known severe allergic reactions associated with Cosentyx?

A: Yes, the prescribing information includes warnings that serious allergic reactions, including anaphylaxis, can occur. For patient safety, treatment is contraindicated (must not be used) in patients with a prior severe allergic reaction to the drug.

Q: Does using alcohol interfere with the way Cosentyx works?

A: Official regulatory documents state that no specific interactions with alcohol are known. Therefore, there are no formal warnings about alcohol being restricted from a drug interaction perspective.

Q: Is Cosentyx generally used alone or with other medications?

A: Regulatory information indicates that co-administration with other biologic immunomodulators is not established and may carry an increased risk of infection. However, the use of conventional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, is not excluded from use with this medication.

Q: What kind of monitoring or blood tests are required when on Cosentyx?

A: Patients must be evaluated for active and latent tuberculosis (TB) infection prior to starting treatment. Additionally, official documents advise that testing for Hepatitis B virus (HBV) infection is to be considered, and patients with positive serology should be monitored for potential reactivation during treatment.

Q: What is the purpose of the initial 'loading doses' of Cosentyx?

A: The official treatment protocol defines the loading phase as an initial intensive period that precedes the long-term maintenance schedule. The purpose of this initial, more frequent dosing is to help establish the drug's therapeutic level in the body more rapidly.

Q: Is Cosentyx a new medication, or has it been around for a while?

A: Cosentyx has been available for a number of years, with its initial approval by the U.S. Food and Drug Administration (FDA) occurring in January 2015.

Q: Does Cosentyx contain any latex components?

A: The official product information specifies that the removable needle cap on some forms of the injection device, such as the SensoReady pen and prefilled syringes, contains a derivative of natural rubber latex.

Q: How is the action of Cosentyx different from general pain relievers?

A: Cosentyx is a monoclonal antibody that works by selectively targeting and neutralizing the inflammatory messenger Interleukin-17A in the immune system. This highly targeted approach is different from general pain relievers, which typically block pain signals or target general inflammation mediators.

Q: Are there any long-term research papers available on patient quality of life with Cosentyx?

A: Research studies have included assessments of the impact on patient quality of life as measured by standardized questionnaires. Data regarding these measures are available from long-term open-label studies for up to five years.

Q: What official warnings are attached to the use of Cosentyx?

A: Official warnings primarily concern the potential for an increased risk of serious infections, including tuberculosis (TB), due to the drug’s mechanism. There is also a warning regarding the potential for new cases or worsening of Inflammatory Bowel Disease (IBD).

Q: What conditions are known to be worsened by Cosentyx?

A: The prescribing information includes a specific warning that new cases or exacerbations (flare-ups) of Inflammatory Bowel Disease (IBD), such as Crohn's disease and ulcerative colitis, have occurred in patients using this medication.

Q: Is Cosentyx approved in all major countries around the world?

A: Official sources indicate that Cosentyx is approved in many countries worldwide, with regulatory approval noted in more than 100 countries for its various conditions of use.

Q: Does official research evidence suggest a benefit in treating joint damage with Cosentyx?

A: Clinical studies, particularly for Psoriatic Arthritis, monitored the rate of progressive structural damage to the joints using X-ray assessments. Findings describe patterns where radiographic progression was observed to be inhibited through 52 weeks in a high proportion of patients receiving the treatment.

Q: What is the potential impact of Cosentyx on mental health or mood?

A: Clinical trials have monitored psychiatric adverse effects and have reported serious psychiatric adverse events in some patients. Findings from studies in conditions like Hidradenitis Suppurativa also described improvement in emotional well-being measures.

How to Store and Dispose of Cosentyx

Cosentyx (secukinumab) must be stored in a refrigerator between 36^circF to 46^circF (2^circC to 8^circC).

Storage Requirements

Condition	Requirement
Prohibited	Do not freeze and do not shake the pen or syringe.
Protection	Keep the medicine in its original carton until use to protect it from light.
Child Safety	Keep Cosentyx out of the reach of children.

Stability and Handling

The product may be stored at room temperature, not exceeding 86^circF (30^circC), for a single period of up to 4 days. If unused and still within this temperature limit, it may be returned to the refrigerator only one time. Any product that has been frozen or stored outside refrigeration for more than 4 days must be discarded.

Disposal

Used pens and syringes must be placed immediately in an FDA-cleared sharps disposal container. Do not dispose of used or expired medicine in household trash or down the drain.